These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1389 related articles for article (PubMed ID: 23825154)

  • 1. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
    Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
    Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the DNA damage response in oncology: past, present and future perspectives.
    Basu B; Yap TA; Molife LR; de Bono JS
    Curr Opin Oncol; 2012 May; 24(3):316-24. PubMed ID: 22476188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CBP and p300 histone acetyltransferases contribute to homologous recombination by transcriptionally activating the BRCA1 and RAD51 genes.
    Ogiwara H; Kohno T
    PLoS One; 2012; 7(12):e52810. PubMed ID: 23285190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.
    Huehls AM; Wagner JM; Huntoon CJ; Karnitz LM
    Mol Pharmacol; 2012 Oct; 82(4):767-76. PubMed ID: 22833573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
    Smith J; Tho LM; Xu N; Gillespie DA
    Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative measurement of alterations in DNA damage repair (DDR) pathways using single cell network profiling (SCNP).
    Rosen DB; Leung LY; Louie B; Cordeiro JA; Conroy A; Shapira I; Fields SZ; Cesano A; Hawtin RE
    J Transl Med; 2014 Jun; 12():184. PubMed ID: 24965603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An insight into understanding the coupling between homologous recombination mediated DNA repair and chromatin remodeling mechanisms in plant genome: an update.
    Banerjee S; Roy S
    Cell Cycle; 2021 Sep; 20(18):1760-1784. PubMed ID: 34437813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Garcinol, a histone acetyltransferase inhibitor, radiosensitizes cancer cells by inhibiting non-homologous end joining.
    Oike T; Ogiwara H; Torikai K; Nakano T; Yokota J; Kohno T
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):815-21. PubMed ID: 22417805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of DNA Replication Stress by CHK1 Leads to Chemoresistance Despite a DNA Repair Defect in Homologous Recombination in Breast Cancer.
    Meyer F; Becker S; Classen S; Parplys AC; Mansour WY; Riepen B; Timm S; Ruebe C; Jasin M; Wikman H; Petersen C; Rothkamm K; Borgmann K
    Cells; 2020 Jan; 9(1):. PubMed ID: 31963582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of switch from ATM to ATR signaling at the sites of DNA damage induced by low and high LET radiation.
    Saha J; Wang M; Cucinotta FA
    DNA Repair (Amst); 2013 Dec; 12(12):1143-51. PubMed ID: 24238855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factors.
    Ogiwara H; Ui A; Otsuka A; Satoh H; Yokomi I; Nakajima S; Yasui A; Yokota J; Kohno T
    Oncogene; 2011 May; 30(18):2135-46. PubMed ID: 21217779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.
    Bryant HE; Helleday T
    Nucleic Acids Res; 2006; 34(6):1685-91. PubMed ID: 16556909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA damage response pathways in tumor suppression and cancer treatment.
    Liang Y; Lin SY; Brunicardi FC; Goss J; Li K
    World J Surg; 2009 Apr; 33(4):661-6. PubMed ID: 19034564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
    Haynes B; Murai J; Lee JM
    Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors.
    Wang YS; Chen J; Cui F; Wang H; Wang S; Hang W; Zeng Q; Quan CS; Zhai YX; Wang JW; Shen XF; Jian YP; Zhao RX; Werle KD; Cui R; Liang J; Li YL; Xu ZX
    Oncotarget; 2016 Nov; 7(45):73389-73401. PubMed ID: 27705915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
    Gralewska P; Gajek A; Marczak A; Rogalska A
    J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin-Mediated HDAC Inhibition Suppresses the DNA Damage Response and Contributes to Increased DNA Damage Sensitivity.
    Wang SH; Lin PY; Chiu YC; Huang JS; Kuo YT; Wu JC; Chen CC
    PLoS One; 2015; 10(7):e0134110. PubMed ID: 26218133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition.
    Xia Q; Cai Y; Peng R; Wu G; Shi Y; Jiang W
    Int J Oncol; 2014 Mar; 44(3):735-44. PubMed ID: 24378347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.